Strive announced that its SATS IPO raised enough capital to potentially purchase more than 7,500 Bitcoin, which could position the company as the second-largest corporate Bitcoin holder. However, this figure represents the buying capacity from the funds raised, not actual Bitcoin acquired yet. The key next step is for Strive to confirm any Bitcoin purchases and disclose the final amount acquired. This development highlights the company's potential expansion in corporate Bitcoin holdings, pending actual acquisition.
Strive's SATS IPO and its potential Bitcoin buying power provide context for cryptocurrency market activity. For readers following crypto assets, here is Pluang's market snapshot as of Oct 21, 2026 05:11 WIB: Out of 50 major cryptocurrencies, 44 rose and 5 fell today. Among notable movers, COTI increased by 5.32% to Rp202 with a typical hold time of 121 days and a Pluang order activity skewed 67% Sell / 33% Buy, while AXS rose 5.20% to Rp18,925 but saw 100% Sell orders, contrasting with XTZ which gained 5.07% to Rp5,675 with a similar 67% Sell / 33% Buy split.
Medical Informatics Corp. has launched the Sickbay Experience Demo Center at Texas Medical Center's Helix Park, showcasing its FDA-cleared Sickbay platform. This interactive center demonstrates how real-time patient data from various medical devices ...
Grupo Aeroportuario del Pacífico reported Q3 2026 earnings per share of $2.66 and revenue of $632.9 million, both below analyst expectations. Despite the miss, the company saw a 13.2% rise in revenue excluding construction services and a 19.2% increa...
Northern Trust is set to report its Q3 2026 earnings with analysts forecasting a 24.9% rise in earnings per share to $2.86 and an 11.8% increase in revenue to $2.26 billion. Growth is driven by an 11.4% increase in net interest income and a 12.1% ris...
Moody's is expected to report Q3 2026 earnings of around $4.25 per share on revenue near $2.08 billion, driven by steady demand for credit ratings and growth in Moody's Analytics, especially from recurring subscriptions and AI tools. While Moody's In...
Raymond James increased its price target for Rapport Therapeutics to $86 following positive Phase 2 trial results of RAP-219, a drug treating acute bipolar mania. The trial showed statistically significant improvement in patients and a favorable safe...
